Recovery of a dog from aplastic anaemia after treatment with mycophenolate mofetil

Yuki, Masashi; Sugimoto, Noriaki; Otsuka, Hiromi; Tanahashi, Sakiko; Katoh, Mayuko; Hirano, Takashi; Nishii, Naohito; Suzuki, Keitarou

doi:10.1111/j.1751-0813.2007.00201.x

Cited by 22 publications

(23 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common adverse reactions associated with MMF administration in dogs with naturally occurring immune‐mediated diseases are weight loss, GI upset and mild allergic reactions during parenteral administration (Dewey et al , Lange et al ). In this case series, GI side effects due to MMF therapy were common, which is consistent with previous studies (Dewey et al , Banyard & Hassett , Broaddus et al , Yuki et al , Abelson et al , Dewey et al , Ginel et al , Wang et al , West & Hart ).…”

Section: Discussionsupporting

confidence: 92%

Treatment of five haemodynamically stable dogs with immune‐mediated thrombocytopenia using mycophenolate mofetil as single agent

Yau¹,

Bianco²

2014

J of Small Animal Practice

View full text Add to dashboard Cite

Five dogs were presumptively diagnosed with immune-mediated thrombocytopenia. As they had all been chronically treated with non-steroidal anti-inflammatory drugs, administration of immunosuppressive doses of corticosteroids was considered contraindicated. Non-steroidal anti-inflammatory drugs were temporarily discontinued in all the dogs and mycophenolate mofetil was introduced as first-line single immunomodulatory therapy. This treatment protocol resulted in complete remission of immune-mediated thrombocytopenia in all the dogs, and mycophenolate mofetil was discontinued after several months of therapy in four of the five dogs with no relapses, even when non-steroidal anti-inflammatory drug administration was resumed. The remaining dog required continued mycophenolate mofetil therapy to avoid relapse. One dog experienced diarrhoea, and another dog had diarrhoea and decreased appetite.

show abstract

Section: Discussionsupporting

confidence: 92%

Treatment of five haemodynamically stable dogs with immune‐mediated thrombocytopenia using mycophenolate mofetil as single agent

Yau¹,

Bianco²

2014

J of Small Animal Practice

View full text Add to dashboard Cite

show abstract

“…In small animals, MMF (CellCept Intravenous; Genentech) has been used for organ transplantation and immune-mediated diseases (Creevy et al 2003, Broaddus et al 2006, Lupu et al 2006, Yuki et al 2007, Abelson 2009, Dewey et al 2010, Bacek & Macintire 2011. Canine studies show rapid oral absorption with significant enterohepatic circulation with oral bioavailability reported as 54, 65 and 87% after 10, 15 and 20 mg/kg oral dosing, respectively (Langman et al 1996, Lupu et al 2006.…”

Section: Resultsmentioning

confidence: 99%

“…Another report described successful treatment of canine aplastic anaemia using 10 mg/kg MMF, every 12 hours (Yuki et al . ).…”

Section: Discussionmentioning

confidence: 97%

“…Twenty-six MMF dogs (87%) received anticoagulants, including a mean dose of 0·6 mg/kg (range 0·5 to 1·3 mg/kg) aspirin, orally, every 24 hours; a mean dose of 300 U/kg (range 100 to 600 U/kg) heparin, subcutaneously (sc), every 8 hours; or a mean MMF use in the laboratory and veterinary clinical setting has been described previously (Yu et al 1998, Yuki et al 2007, Abelson 2009, Dewey et al 2010, Ginel et al 2010, Bacek & Macintire 2011. Its use with prednisolone in canine idiopathic IMHA induced resolution of anaemia in seven of eight dogs, with mild enteritis seen in 1 dog (Nielsen 2005).…”

Section: Methodsmentioning

confidence: 99%

“…Its use with prednisolone in canine idiopathic IMHA induced resolution of anaemia in seven of eight dogs, with mild enteritis seen in 1 dog (Nielsen 2005). Another report described successful treatment of canine aplastic anaemia using 10 mg/kg MMF, every 12 hours (Yuki et al 2007).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations